Premier Research Launches Premier Consulting Business Unit, Creating Unified Regulatory and Strategic Product Development Brand
Morrisville, N.C., February 22, 2022 — Premier Research launched Premier Consulting today by consolidating two legacy brands within its portfolio — Regulatory Professionals, Inc. (RPI) and Camargo Pharmaceutical Services. Premier Consulting is a unified strategic product development and global regulatory consulting brand positioned for market leadership in support of emerging biotech and specialty pharma companies.
The new structure represents a fusion of talent and a union of two deep benches that share a customer-centric culture with broad expertise in end-to-end strategy, regulatory, nonclinical, CMC, quality, and commercial solutions.
“We’ve listened closely to customers as we’ve shaped this new business unit and integrated all we’ve learned in working with the true innovators in this industry — the startups and small to midsize biotech,” Premier Consulting President Dr. Sameena Sharif said.
“In merging the best of both brands, we are zeroed in on strategic product development and global regulatory consulting,” Sharif added. “As Premier Consulting, we are perfectly situated to deliver the expansive range of product development services demanded by today’s fast-evolving regulatory environment.”
Sharif noted that the accelerating complexity of that regulatory landscape has put a premium on services that are streamlined, nimble, and flexible. “What sponsors who are transforming life sciences with breakthrough innovation need more than ever,” Sharif said, “is specialized strategy, customized product development support, and spot-on regulatory guidance. We not only navigate sponsors through the global regulatory maze, but we also accelerate and de-risk development so that the right medicines reach the right patients faster.”
Sharif added that over the past year more therapies than ever were designated as first-in-class by the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), and more used the accelerated approval pathway as well. “There has been a growing emphasis on novel therapeutics,” she said, “which present their own special and significant challenges. With our Built for BiotechSM core capabilities, Premier Consulting can guide sponsors in all stages of product development and into commercialization. Not least of all, we understand the imperatives among emerging biotech and specialty pharma companies for high-quality but cost-effective solutions that support their scientific, regulatory, and financial goals.”
About Premier Consulting
Premier Consulting is a strategic product development and global regulatory consulting brand dedicated to supporting the specialized needs of emerging biotech and specialty pharma companies. These small to midsize companies are the very heart of drug development. Like them, we are dedicated to the patient journey and driven by the challenges of bringing new life-saving technologies to market.
As a business unit of Premier Research, we are informed by our Built for BiotechSM core capabilities and deliver end-to-end strategy, regulatory, nonclinical, CMC, quality, and commercial solutions that are best in class. With a customer-centric culture, we pair efficiency with quality as we guide sponsors every step of the way to commercialization. We tailor development plans to meet the most rigorous global regulatory requirements and deliver results for sponsors — and the patients they serve.